Janssen R&D Ireland — CureCurrent

Published trials7

Recruiting shown0

Roles1

SourceClinicalTrials.gov

Clinical trials

7 shown

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected ParticipantsNCT02269917 · lead sponsor · 2015-03-01

A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted ConditionsNCT01619527 · lead sponsor · 2012-04-01

A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of DigoxinNCT01519128 · lead sponsor · 2012-01-01

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1NCT01479868 · lead sponsor · 2011-10-01

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected PatientsNCT01422330 · lead sponsor · 2011-09-01

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1NCT01266902 · lead sponsor · 2011-02-01

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV PatientsNCT00896051 · lead sponsor · 2009-08-01

Sponsor roles

lead sponsor7

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.